# New Adrenaline Devices for Treating Anaphylaxis: Results of a Joint Survey From the European Anaphylaxis Registry and the Allergy‐Vigilance Network

## TL;DR

Allergy specialists highlight key features and barriers for new adrenaline devices to treat anaphylaxis, emphasizing the need for better data and recommendations.

## Contribution

The paper presents new insights from allergy-trained physicians on desired features and barriers for next-generation adrenaline auto-injectors.

## Key findings

- Prolonged shelf life and improved storage conditions were ranked as very important features for new adrenaline devices.
- A history of multiple adrenaline injections or ICU admission were identified as major barriers to adopting new devices.
- Allergy specialists emphasized the importance of clinical data and society recommendations to reduce adoption barriers.

## Abstract

Adrenaline auto‐injectors (AAI) are underused to treat anaphylaxis. New adrenaline devices are currently under investigation or have been recently marketed. This survey aimed to assess the perspectives from allergy‐trained physicians regarding the AAI use and their expectations about new adrenaline devices.

This electronic survey was created by the European Anaphylaxis Registry and Allergy‐Vigilance Network. It was proposed to their participants (March–April 2025) who were asked to rank their responses on a 11‐point Likert scale (0: ‘not important’ to 10: ‘very important’). Results are presented as median with interquartile range.

One hundred and seventy‐five physicians (allergists, 59.4%) participated in this survey. There were only few barriers to AAI prescriptions. Up to 65% of participants estimated the following features as very important for new adrenaline devices: prolonged shelf life (9 [7–10]), improved storage conditions (9 [5–9]), detailed pharmacokinetic‐pharmacodynamic data (8 [7–10]), optimised dose ranging (8 [7–10]), availability in public spaces (8 [7–10]), devices easy to carry (8 [7–9]), needle‐free device (8 [6–10]). A history of anaphylaxis treated with > 1 adrenaline injection (7 [4–9]) or admitted to intensive care unit (7 [3–8]) were reported as the most important barriers to use new adrenaline devices. 75% of participants felt that recommendations from allergy societies and more clinical data are important measures to reduce barriers to new adrenaline devices.

Our data provide insights from allergy‐trained physicians into AAI limitations and expectations on new adrenaline devices. To advance them, input from allergy societies and more clinical data from anaphylaxis patients are needed.